Results 11 to 20 of about 38,609 (257)

Extended-Interval Dosing of Aminoglycosides in Pediatrics: A Narrative Review

Journal of Pediatrics Review, 2015
Aminoglycosides (AGs) are frequently used in pediatric settings, especially for empiric treatment of early-onset neonatal sepsis. Although AGs are used for several decades, the optimum method of administration and their dosing schemes needs more ...
Ebrahim Salehifar, Mohammad Reza Rafati
doaj   +4 more sources

Extended interval dosing with ocrelizumab in multiple sclerosis [PDF]

Multiple Sclerosis Journal
Background: This study investigates clinical and biomarker differences between standard interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple sclerosis (MS). Methods: This is a prospective, double ...
Frederik Novak
exaly   +8 more sources

Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation – a retrospective study [PDF]

BMC Pediatrics, 2019
Background Although aminoglycosides are routinely used in neonates, controversy exists regarding empiric dosing regimens. The objectives were to determine gentamicin pharmacokinetics in neonates, and develop initial mg/kg dosing recommendations that ...
Monique Bergenwall, Sandra A. N. Walker, Marion Elligsen, Dolores C. Iaboni, Carla Findlater, Winnie Seto, Eugene Ng   +6 more
doaj   +4 more sources

Extended interval dosing of natalizumab: a two-center, 7-year experience [PDF]

Therapeutic Advances in Neurological Disorders, 2014
Background: The enthusiasm for natalizumab, a highly efficacious agent in the treatment of multiple sclerosis (MS), has been tempered by the risks of progressive multifocal leukoencephalopathy associated with its use, and strategies to minimize those ...
Roberto Bomprezzi, Siddharama Pawate
doaj   +3 more sources

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab [PDF]

Multiple Sclerosis Journal, 2022
BACKGROUND: Accumulating evidence supports the efficacy of administering natalizumab (NZ) with extended-interval dosing (EID) in patients with relapsing-remitting multiple sclerosis (RRMS).
Magnus Johnsson, Helen H Farman, Clas Malmeström   +2 more
exaly   +4 more sources

An extended interval dosing method for gentamicin in neonates [PDF]

Journal of Antimicrobial Chemotherapy, 2001
Traditional gentamicin dosing every 8-24 h depending on age and weight in neonates does not provide the ideal concentration-time profile to both optimize the concentration-dependent killing by aminoglycosides and minimize toxicity. Fifty-three neonates were audited prospectively while receiving gentamicin 2.5 mg/kg every 8-24 h, aiming for peak ...
Stickland, M. D., Kirkpatrick, C., Begg, E., Duffull, S. B., Oddie, S. J., Darlow, B.   +5 more
openaire   +6 more sources

Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience [PDF]

International Journal of Molecular Sciences
Ocrelizumab (OCR), an anti-CD20 monoclonal antibody, is approved for treating relapsing remitting (RR) and primary progressive (PP) multiple sclerosis (MS).
Gianmarco Bellucci, Maria Chiara Buscarinu, Marco Salvetti   +2 more
exaly   +4 more sources

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine [PDF]

Cell, 2021
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers.
Rebecca Payne, Stephanie Longet, Donal Skelly   +2 more
exaly   +6 more sources

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? [PDF]

Neurotherapeutics, 2020
Extending the natalizumab interval after the 24th administration could reduce the risk of progressive multifocal leukoencephalopathy (PML). The objective is to evaluate the noninferiority of the efficacy of an extended interval dosing (EID) compared with the standard interval dosing (SID) of natalizumab.
Clerico, Marinella, De Mercanti, Stefania Federica, Signori, Alessio, Iudicello, Marco, Cordioli, Cinzia, Signoriello, Elisabetta, Lus, Giacomo, Bonavita, Simona, Lavorgna, Luigi, Maniscalco, Giorgia Teresa, Curti, Erica, Lorefice, Lorena, Cocco, Eleonora, Nociti, Viviana, Mirabella, Massimiliano, Baroncini, Damiano, Mataluni, Giorgia, Landi, Doriana, Petruzzo, Martina, Lanzillo, Roberta, Gandoglia, Ilaria, Laroni, Alice, Frangiamore, Rita, Sartori, Arianna, Cavalla, Paola, Costantini, Gianfranco, Sormani, Maria Pia, Capra, Ruggero   +27 more
openaire   +8 more sources

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma. [PDF]

Clin Pharmacol Ther
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Malmberg R, Hofman MM, Ashad F, Daloul A, Oosterveld S, Basak EA, Oomen-de Hoop E, van der Veldt AAM, Joosse A, van Leeuwen RWF, Mathijssen RHJ.   +10 more
europepmc   +4 more sources